Jump to content

Perflubron

From Wikipedia, the free encyclopedia
(Redirected from C8BrF17)
Perflubron
Clinical data
ATC code
Identifiers
  • 1-Bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.391 Edit this at Wikidata
Chemical and physical data
FormulaC8BrF17
Molar mass498.965 g·mol−1
3D model (JSmol)
Density1.93 g/cm3
Melting point6 °C (43 °F)
Boiling point142 °C (288 °F)
  • FC(F)(C(F)(F)C(Br)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
  • InChI=1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26
  • Key:WTWWXOGTJWMJHI-UHFFFAOYSA-N

Perflubron (INN/USAN, or perfluorooctyl bromide; brand name Imagent) is a contrast medium for magnetic resonance imaging, computer tomography and sonography.[1] It was approved for this use in the United States by the Food and Drug Administration in 1993.[2]

Experimental research

[edit]

Perflubron has also been tested experimentally for use in liquid breathing in premature infants with respiratory distress.[3][4]

This molecular model of Perflubron is color-coded by electron density to illustrate the positive polarisation of the large bromine atom by the inductively electron-withdrawing perfluorooctyl chain.

References

[edit]
  1. ^ Mattrey RF (February 1989). "Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging". AJR. American Journal of Roentgenology. 152 (2): 247–52. doi:10.2214/ajr.152.2.247. PMID 2643258.
  2. ^ FDA Approved Drug Products
  3. ^ Wolfson MR, Kechner NE, Roache RF, DeChadarevian JP, Friss HE, Rubenstein SD, Shaffer TH (February 1998). "Perfluorochemical rescue after surfactant treatment: effect of perflubron dose and ventilatory frequency". Journal of Applied Physiology. 84 (2): 624–40. doi:10.1152/jappl.1998.84.2.624. PMID 9475875.
  4. ^ Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, et al. (September 1996). "Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group". The New England Journal of Medicine. 335 (11): 761–7. doi:10.1056/NEJM199609123351101. PMID 8778584.